Listen to our latest Investing Matters Podcast episode 'Uncovering opportunities with investment trusts' with The AIC's Richard Stone here.
@Gemstar
'If Dr Smith and other key executives are at the Morgan conference in the States this week, they are not going to issue a seminal RNS until they return'
Surely AS knew he was attending the Morgan conference when he issued the Dec RNS advising early Jan update?
Its also not an unreasonable hypothesis to believe that:
1. Higher volume doses of Dox via AVA6K Vs straight dox
2. Improved targeting via Ava6k Vs straight Dox;
Will deliver vastly improved efficacy on the tumor (shrinkage/elimination)
Fingers crossed for all those taking part!
Rah,
I understand the point and I'm not expecting much/any data on efficacy. Confirmation of Dox in the tumor will suffice however...... If AVA6K is really targeted, there is a possibility of much larger volume of Dox hitting the TME than there would be with straight Dox. If this is the case (real possibility it is) then efficacy data might be off the chart Vs straight dox.
Patients with the following conditions are unable to be dosed with straight dox:
Bone marrow problem (eg, drug-induced myelosuppression)
Heart disease
Liver disease
I assume such patients would benefit from AVA6k and early efficacy would be apparent
You make a lot of good points, RAH, but I think you are wrong in this instance.
Scans will be regular for each patient and efficacy will be monitored bi weekly.
'Most patients on this trial will have previously been unresponsive to chemotherapy'
The above is not true. Most patients are likely too unwell to survive straight dox/chemo, hence are being offered chance to partake in this trial.